RT Journal Article SR Electronic T1 FDA's misplaced priorities: premarket review under the Family Smoking Prevention and Tobacco Control Act JF Tobacco Control JO Tob Control FD BMJ Publishing Group Ltd SP 246 OP 253 DO 10.1136/tobaccocontrol-2015-052391 VO 25 IS 3 A1 Desmond Jenson A1 Joelle Lester A1 Micah L Berman YR 2016 UL http://tobaccocontrol.bmj.com/content/25/3/246.abstract AB Among other key objectives, the 2009 Family Smoking Prevention and Tobacco Control Act was designed to end an era of constant product manipulation by the tobacco industry that had led to more addictive and attractive products. The law requires new tobacco products to undergo premarket review by the US Food and Drug Administration (FDA) before they can be sold. To assess FDA's implementation of its premarket review authorities, we reviewed FDA actions on new product applications, publicly available data on industry applications to market new products, and related FDA guidance documents and public statements. We conclude that FDA has not implemented the premarket review process in a manner that prioritises the protection of public health. In particular, FDA has (1) prioritised the review of premarket applications that allow for the introduction of new tobacco products over the review of potentially non-compliant products that are already on the market; (2) misallocated resources by accommodating the industry's repeated submissions of deficient premarket applications and (3) weakened the premarket review process by allowing the tobacco industry to market new and modified products that have not completed the required review process.